EZH2 and neuroblastoma: Furthermore, the results suggest that EZH2 inhibitors are promising candidates for clinical testing in combination with anti‐GD2 antibodies, and may enhance therapeutic outcomes for children with neuroblastoma—particularly those who have relapsed or show resistance to current GD2‐targeted treatments [151].